Anti-csp antibody variants
Anti-cyclosporine antibodies are developed to address the lack of effective CSP-targeting antibodies in malaria treatments, providing therapeutic options for malaria prevention and treatment.
HK40134683APending Publication Date: 2026-07-10ATRECA INC
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- ATRECA INC
- Filing Date
- 2026-04-16
- Publication Date
- 2026-07-10
AI Technical Summary
Technical Problem
Current treatments for malaria lack effective antibodies targeting cyclosporine (CSP), which are essential for treating or preventing the disease.
Method used
Development of anti-cyclosporine (CSP) antibodies and compositions comprising these antibodies for therapeutic use against malaria, along with methods for selecting and producing such antibodies.
Benefits of technology
Provides antibodies that effectively target CSP, offering potential treatments and prevention strategies for malaria.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies. Also disclosed are methods of producing the disclosed antibodies and methods of treating or preventing malaria using the same. Also disclosed are methods of selecting an antibody as an anti-malaria therapeutic antibody.
Need to check novelty before this filing date? Find Prior Art